Clinuvel Pharmaceuticals Limited American Depositary Shares CUVL

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.

Con 177 acciones de CUVL (USD 997,40) habrías recibido USD 7,08 en dividendos en los últimos 12 meses.

• GlobeNewswire Inc. 27 ago

  A decade of profitability provides foundation for CLINUVEL’s U.S. expansion

  CLINUVEL Pharmaceuticals announced its tenth consecutive annual profit for FY2026 with revenues of $94.0 million and net profit after tax of $33.9 million. The company declared a $0.05 per share dividend and increased cash reserves to $252.1 million, providing financial independence to pursue expansion strategy, particularly in North America. Despite marginal revenue decline due to U.S. market competition and inventory practice changes, the company maintained disciplined expense control and achieved record SCENESSE treatment volumes.

  

• GlobeNewswire Inc. 23 jul

  CLINUVEL implements strategic reorganisation to refocus on U.S. markets

  CLINUVEL Pharmaceuticals announced a strategic reorganisation effective January 1, 2027, relocating its corporate headquarters from Australia to the United States and reducing its global workforce by 10-20%. The restructuring aims to strengthen U.S. regulatory engagement, focus operations on the U.S. pharmaceutical market, and unlock deeper capital pools from U.S. investors who prefer U.S.-listed companies. The move is driven by the company's recognition that U.S.-listed specialty pharma companies command higher valuation multiples and that over 66% of its shareholder base is already foreign investors.